Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis.

Corpechot, Christophe and Chazouillères, Olivier and Belnou, Pierre and Montano-Loza, Aldo J and Mason, Andrew and Ebadi, Maryam and Eurich, Dennis and Chopra, Sascha and Jacob, Dietmar and Schramm, Christoph and Sterneck, Martina and Bruns, Tony and Reuken, Philipp and Rauchfuss, Falk and Roccarina, Davide and Thorburn, Douglas and Gerussi, Alessio and Trivedi, Palak J and Hirschfield, Gideon M and McDowell, Patrick and Nevens, Frederik and Boillot, Olivier and Bosch, Alexie and Giostra, Emiliano and Conti, Filomena and Poupon, Raoul and Parés, Albert and Reig, Anna and Donato, Maria Francesca and Malinverno, Federica and Floreani, Annarosa and Russo, Francesco Paolo and Cazzagon, Nora and Verhelst, Xavier and Goet, Jorn and Harms, Maren and van Buuren, Henk and Hansen, Bettina and Carrat, Fabrice and Dumortier, Jérôme (2020) Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis. Journal of hepatology. ISSN 1600-0641. Full text available to UHB Athens account holders via OpenAthens

Full text not available from this repository.
Official URL: https://www.journal-of-hepatology.eu/article/S0168...

Abstract

BACKGROUND & AIMS

Recurrence of primary biliary cholangitis (PBC) after liver transplantation (LT) is frequent and able to impair graft and patient survival. Ursodeoxycholic acid (UDCA) is the current standard therapy for PBC. We investigated the effect of preventive exposure to UDCA on the incidence and long-term consequences of PBC recurrence after LT.

METHODS

We did a retrospective cohort study including 780 patients transplanted for PBC from 1983 to 2017 in 16 centers and 9 countries and followed-up for a median time of 11 years. Among them, 190 received UDCA (10-15 mg/kg/d) preventively. The primary outcome was PBC recurrence as proven by histology. The secondary outcomes were graft loss, liver-related death, and all-cause death. The association between preventive UDCA and outcomes was quantified using multivariable-adjusted Cox and restricted mean survival time (RMST) models.

RESULTS

While recurrence of PBC significantly shortened graft and patient survivals, preventive exposure to UDCA was associated with reduced risk for PBC recurrence (adjusted hazard ratio, 0.41; 95%CI, 0.28 - 0.61; p<0.0001), graft loss (0.33; 0.13 - 0.82; p<0.05), liver-related death (0.46; 0.22 - 0.98; p<0.05), and all-cause death (0.69; 0.49 - 0.96; p<0.05). RMST analysis showed consistent results with a survival gain of 2.26 years (95%CI 1.28 - 3.25) over 20 years. Exposure to cyclosporine rather than to tacrolimus added to the preventive effect of UDCA against PBC recurrence and all-cause death.

CONCLUSIONS

Preventive UDCA after LT for PBC is associated with reduced risk for disease recurrence, graft loss, and death. Regimen combining cyclosporine and preventive UDCA is associated with the lowest risk of PBC recurrence and mortality.

Item Type: Article
Additional Information: Full text available to UHB Athens account holders via OpenAthens
Subjects: WI Digestive system. Gastroenterology
Divisions: Planned IP Care > Gastroentrology
Related URLs:
Depositing User: Mr Philip O'Reilly
Date Deposited: 17 Apr 2020 15:34
Last Modified: 17 Apr 2020 15:34
URI: http://www.repository.uhblibrary.co.uk/id/eprint/2996

Actions (login required)

View Item View Item